124 related articles for article (PubMed ID: 3096324)
21. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
[TBL] [Abstract][Full Text] [Related]
22. Effect of alpha-interferon, 17 beta-estradiol, and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF 7 cells.
Bezwoda WR; Meyer K
Cancer Res; 1990 Sep; 50(17):5387-91. PubMed ID: 2386944
[TBL] [Abstract][Full Text] [Related]
23. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018.
Bronzert DA; Greene GL; Lippman ME
Endocrinology; 1985 Oct; 117(4):1409-17. PubMed ID: 4029083
[TBL] [Abstract][Full Text] [Related]
24. Counteraction of estradiol-induced activation of tissue-type plasminogen activator in a human breast cancer cell line by an anti-estrogen, LY117018.
Uchiumi T; Mizoguchi H; Hagino Y; Kohno K; Kuwano M
Int J Cancer; 1991 Jan; 47(1):80-5. PubMed ID: 1702405
[TBL] [Abstract][Full Text] [Related]
25. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
26. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen.
Horwitz KB; Koseki Y; McGuire WL
Endocrinology; 1978 Nov; 103(5):1742-51. PubMed ID: 748014
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of estrogen stimulated mitogenesis by 3-phenylacetylamino-2,6-piperidinedione and its para-hydroxy analog.
Copland JA; Hendry LB; Chu CK; Wood JC; Wrenn RW; Pantazis CG; Mahesh VB
J Steroid Biochem Mol Biol; 1993 Oct; 46(4):451-62. PubMed ID: 8217876
[TBL] [Abstract][Full Text] [Related]
28. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
29. The regulation of progesterone receptor by 17 beta estradiol and tamoxifen in the Zr-75-1 human breast cancer cell line in defined medium.
Allegra JC; Korat O; Do HM; Lippman M
J Recept Res; 1981; 2(1):17-27. PubMed ID: 6270327
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
31. In vitro effects of estradiol, dydrogesterone, tamoxifen and cyclophosphamide on proliferation vs. death in human breast cancer cells.
Franke HR; Kole S; Ciftci Z; Haanen C; Vermes I
Cancer Lett; 2003 Feb; 190(1):113-8. PubMed ID: 12536084
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Bakker GH; Setyono-Han B; Henkelman MS; de Jong FH; Lamberts SW; van der Schoot P; Klijn JG
Cancer Treat Rep; 1987 Nov; 71(11):1021-7. PubMed ID: 3119199
[TBL] [Abstract][Full Text] [Related]
33. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
[TBL] [Abstract][Full Text] [Related]
34. Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer.
Waseda N; Kato Y; Imura H; Kurata M
Cancer Res; 1981 May; 41(5):1984-8. PubMed ID: 7214366
[TBL] [Abstract][Full Text] [Related]
35. Isolation and characterization of an estrogen-inhibited variant derived from the MCF-7 breast cancer cell line.
Bronzert DA; Triche TJ; Gleason P; Lippman ME
Cancer Res; 1984 Sep; 44(9):3942-51. PubMed ID: 6744309
[TBL] [Abstract][Full Text] [Related]
36. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
37. LHRH-agonist treatment in clinical and experimental human breast cancer.
Klijn JG; de Jong FH; Lamberts SW; Blankenstein MA
J Steroid Biochem; 1985 Nov; 23(5B):867-73. PubMed ID: 3935869
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.
Murphy CS; Pink JJ; Jordan VC
Cancer Res; 1990 Nov; 50(22):7285-92. PubMed ID: 2224859
[TBL] [Abstract][Full Text] [Related]
39. Estrogen control of progesterone receptor induction in human breast cancer: role of nuclear estrogen receptor.
Horwitz KB; McGuire WL
Adv Exp Med Biol; 1979; 117():95-110. PubMed ID: 474293
[TBL] [Abstract][Full Text] [Related]
40. Regulation of breast tumor growth by high dose estrogen is independent of the presence of estrogen receptors.
Hug V; Drewinko B; Hortobagyi GN; Blumenschein G
Breast Cancer Res Treat; 1985; 6(3):237-40. PubMed ID: 4092099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
